See where biotech dealmaking and financing are headed in 2026
After years of volatility, biotech capital markets are entering a new phase. In 2025, fundraising, licensing, and M&A have begun to stabilise—though with a sharper focus on selectivity, value, and strategic fit.
Download the Biopharma deals & financing outlook 2026 (webinar and report) for a clear, data-backed view of the trends defining today’s market—and what they mean for biotech and pharma leaders planning for the year ahead.
Inside the Biopharma deals & financing outlook 2026 package
Biopharma financing and dealmaking in 2025: what’s changing and what comes next
Biopharma dealmaking reached a record $292.6bn in 2025, driven by a shift toward fewer, larger partnerships and increasingly global innovation sourcing.
- Follow the money: See what record deal value reveals about future growth areas.
- Understand how partnering is shifting: From AI-driven deals to China’s growing role in innovation.
- Track high-interest therapeutic areas: Oncology, immunology, metabolic disease, RNA, and next-gen modalities.
The 2026 biotech outlook: financing, partnering and M&A
Join Clarivate and industry leaders as they unpack how biotech financing and dealmaking have evolved over the past 18 months—from a market reset to a more selective recovery.
The discussion covers fundraising conditions, licensing trends, M&A activity, and what biotech CEOs, investors, and BD teams need to do next.
Featured Speakers
What you’ll learn
Understand where capital is flowing
Explore how IPOs, follow-ons, private rounds, and strategic collaborations are shaping biotech financing — and which scientific themes and modalities are attracting the most attention.
Decode how dealmaking is changing
Learn how licensing, partnering, and M&A structures are evolving as companies and investors seek to balance risk, value creation, and strategic flexibility.
Assess the outlook for 2026
Gain perspective on the catalysts and pressure points likely to shape the year ahead, from macro and policy headwinds to payer dynamics, competition, and technology-driven investment themes.
Make better strategic decisions
Use data-backed insight to inform portfolio planning, fundraising strategy, partnering priorities, and go/no-go decisions in a more selective biotech market.
Powered by Clarivate
Get the complete picture for biotech strategy, financing, and dealmaking. Discover the tools industry leaders use to monitor the market, benchmark opportunities, and support confident decisions.
Cortellis Deals Intelligence
Comprehensive life sciences deal data with predictive analytics to help evaluate transaction trends, benchmark valuations, and assess the likelihood of deal success across every stage.
Why top life sciences companies trust Clarivate
In a fast-moving market, leadership teams need more than headlines. Clarivate helps decision-makers cut through noise with trusted data, expert insight, and a broader view of the forces shaping biotech financing and dealmaking.
Enable confident decision-making
Use comprehensive deal data, market intelligence, and expert reporting to support leadership discussions around fundraising, partnering, and strategic planning.
Understand competitive and market dynamics
Track how peers, investors, and pharma acquirers are behaving across therapeutic areas, modalities, and stages of development.
See the bigger pictures
Develop a more complete view of the market by combining historical trends, real-time reporting, and expert analysis to inform long-term strategy.